Background
Methods
Study design and participants
Data collection
Statistical analysis
Results
Basic characteristics
Characteristics | Total (n = 107) | Survivors (n = 88) | Non-survivors (n = 19) | P value |
---|---|---|---|---|
Age, years | 51.0 (36.0–65.0) | 44.5 (35.0–58.8) | 73.0 (64.0–81.0) | < 0.001* |
< 45 | 46 (43.0) | 44 (50.0) | 2 (10.5) | 0.002 |
45–59 | 25 (23.4) | 24 (27.3) | 1 (5.3) | 0.041 |
60–75 | 23 (21.5) | 16 (18.2) | 7 (36.8) | 0.119 |
> 75 | 13 (12.1) | 4 (4.5) | 9 (47.4) | < 0.001 |
Sex | 0.003* | |||
Male | 57 (53.3) | 41 (46.6) | 16 (84.2) | |
Female | 50 (46.7) | 47 (53.4) | 3 (15.8) | |
Comorbidity | ||||
Any comorbidity* | 41 (38.3) | 28 (31.8) | 13 (68.4) | 0.003 |
Hypertension | 26 (24.3) | 16 (18.2) | 10 (52.6) | 0.001* |
Cardiovascular disease | 13 (12.1) | 6 (6.8) | 7 (36.8) | 0.002* |
Diabetes | 11 (10.3) | 6 (6.8) | 5 (26.3) | 0.024* |
Chronic liver disease | 6 (5.6) | 5 (5.7) | 1 (5.3) | 1.000 |
Cerebrovascular disease | 6 (5.6) | 3 (3.4) | 3 (15.8) | 0.068 |
COPD | 3 (2.8) | 2 (2.3) | 1 (5.3) | 0.447 |
Chronic kidney disease | 3 (2.8) | 2 (2.3) | 1 (5.3) | 0.447 |
Symptoms and signs | ||||
Fever | 104 (97.2) | 85 (96.6) | 19 (100.0) | 1.000 |
Dry cough | 67 (62.6) | 56 (63.6) | 11 (57.9) | 0.639 |
Fatigue | 69 (64.5) | 55 (62.5) | 14 (73.7) | 0.356 |
Dyspnea | 35 (32.7) | 20 (22.7) | 15 (78.9) | < 0.001* |
Anorexia | 33 (30.8) | 25 (28.4) | 8 (42.1) | 0.241 |
Myalgia | 33 (30.8) | 28 (31.8) | 5 (26.3) | 0.638 |
Pharyngalgia | 12 (11.2) | 11 (12.5) | 1 (5.3) | 0.689 |
Headache | 7 (6.5) | 7 (8.0) | 0 (0) | 0.348 |
Dizziness | 7 (6.5) | 7 (8.0) | 0 (0) | 0.348 |
Diarrhea | 7 (6.5) | 3 (3.4) | 4 (21.1) | 0.018* |
Nausea | 6 (5.6) | 6 (6.8) | 0 (0) | 0.588 |
Vomiting | 3 (2.8) | 2 (2.3) | 1 (5.3) | 0.447 |
Abdominal pain | 2 (1.9) | 1 (1.1) | 1 (5.3) | 0.325 |
Heart rate (bpm) | 86 (75–96) | 85 (75–96) | 90 (78–100) | 0.240 |
Respiratory rate | 20 (19–21) | 20 (19–21) | 22 (20–24) | 0.003* |
Mean arterial pressure (mmHg) | 89 (83–98) | 88 (83–96) | 95 (89–101) | 0.019* |
Onset of symptom to admission (days) | 7.0 (3.5–9.0) | 7.0 (3.0–9.8) | 6.0 (4.0–7.0) | 0.405 |
Onset of symptom to dyspnea (days) | 5.5 (2.0–9.3) | 7.0 (3.3–10.8) | 4.0 (1.8–7.5) | 0.103 |
Onset of symptom to ARDS (days) | 7.5 (4.3–11.0) | 10.0 (6.0–13.0) | 7.0 (3.5–9.0) | 0.081 |
Length of hospital stay (days) | 11.0 (7.0–15.0) | 10.5 (7.0–14.0) | 14.0 (6.0–17.0) | 0.561 |
Laboratory values and radiographic findings
Normal range | Total (n = 107) | Survivors (n = 88) | Non-survivors (n = 19) | P value | |
---|---|---|---|---|---|
White blood cell count, × 109/L | 3.5–9.5 | 4.6 (3.7–6.1) | 4.4 (3.4–5.8) | 6.7 (4.6–10.3) | 0.004* |
Neutrophil count, × 109/L | 1.8–6.3 | 3.1 (2.1–4.7) | 2.8 (2.0–3.9) | 5.4 (3.2–8.5) | < 0.001* |
Lymphocyte count, × 109/L | 1.1–3.2 | 0.9 (0.7–1.2) | 0.9 (0.7–1.3) | 0.8 (0.5–1.1) | 0.121 |
Platelet count, × 109/L | 125–350 | 175 (129–200) | 178 (139–207) | 122 (83–178) | 0.006* |
Prothrombin time, s | 9.4–12.5 | 12.8 (11.9–13.5) | 12.9 (12.0–13.5) | 12.6 (11.9–13.5) | 0.813 |
Activated partial thromboplastin time, s | 25.1–36.5 | 31.7 (29.4–33.9) | 31.7 (29.5–33.5) | 32.7 (27.5–37.0) | 0.850 |
D-dimer, mg/L | 0–500 | 203 (121–358) | 191 (108–327) | 439 (202–1991) | 0.003* |
Creatine kinase, U/L | < 171 | 90 (54–138) | 86 (53–121) | 142 (87–325) | 0.022* |
Creatine kinase-MB, U/L | < 25 | 14 (10–18) | 13 (9–16) | 18 (13–44) | 0.008* |
Lactate dehydrogenase, U/L | 125–243 | 236 (176–369) | 227 (171–329) | 456 (254–588) | 0.010* |
Alanine aminotransferase, U/L | 9–50 | 23 (16–39) | 22 (15–34) | 47 (22–66) | 0.002* |
Aspartate aminotransferase, U/L | 15–40 | 31 (24–47) | 29 (23–41) | 67 (38–90) | < 0.001* |
Total bilirubin, mmol/L | 5–21 | 9.8 (8.4–14.1) | 9.5 (8.4–12.9) | 11.3 (9.4–20.7) | 0.069 |
Blood urea nitrogen, mmol/L | 2.8–7.6 | 4.2 (3.2–5.6) | 3.9 (3.0–4.7) | 6.1 (4.9–10.5) | < 0.001* |
Creatinine, μmol/L | 64–104 | 71 (60–86) | 68 (58–83) | 87 (71–130) | < 0.001* |
Hypersensitive troponin I, > 26.2 pg/mL, no. (%) | < 26.2 | 6 (5.6) | 1 (1.1) | 5 (26.3) | 0.001* |
Multi-lobar involvement on initial radiographs, no. (%) | NA | 90 (84.1) | 73 (83.0) | 17 (89.5) | 0.731 |
Bilateral involvement on radiographs during hospitalization, no. (%) | NA | 105 (98.1) | 86 (97.7) | 19 (100.0) | 1.000 |
Clinical profile and laboratory findings in COVID-19 patients
Complications, treatments, and outcome
Total (n = 107) | Survivors (n = 88) | Non-survivors (n = 19) | |
---|---|---|---|
Complications | |||
Shock | 22 (20.6) | 3 (3.4) | 19 (100.0) |
Acute cardiac injury | 12 (11.2) | 4 (4.5) | 8 (42.1) |
ARDS | 28 (26.2) | 11 (12.5) | 17 (89.5) |
Acute kidney injury | 14 (13.1) | 0 (0.0) | 14 (73.7) |
Evidence of co-infection | |||
Bacterial | 5 (4.7) | 1 (1.1) | 4 (21.1) |
Viral | 12 (11.2) | 10 (11.4) | 2 (10.5) |
Treatment | |||
Antiviral therapy | 105 (98.1) | 87 (98.9) | 18 (94.7) |
Oseltamivir | 95 (88.8) | 77 (87.5) | 18 (94.7) |
Arbidol | 33 (30.8) | 33 (37.5) | 0 (0.0) |
Antibiotic therapy | 85 (79.4%) | 67 (76.1) | 18 (94.7) |
Glucocorticoid therapy | 62 (57.9) | 44 (50.0) | 18 (94.7) |
CRRT | |||
Oxygen therapy | 4 (3.7) | 0 (0.0) | 4 (21.1) |
Oxygen inhalation | 80 (74.8) | 78 (88.6) | 2 (10.5) |
Non-invasive ventilation | 7 (6.5) | 7 (8.0) | 0 (0.0) |
IMV alone | 17 (15.9) | 1 (1.1) | 16 (84.2) |
IMV plus ECMO | 3 (2.8) | 2 (2.3) | 1 (5.3) |
Risk factors associated with death for COVID-19
Variable | Univariable | |
---|---|---|
OR (95% CI) | P value | |
Age | 1.102 (1.054–1.152) | < 0.001* |
Male | 6.114 (1.662–22.485) | 0.006* |
Hypertension | 5.000 (1.748–14.301) | 0.003* |
Diabetes | 4.881 (1.310–18.184) | 0.018* |
Cardiovascular disease | 7.972 (2.290–27.753) | 0.001* |
White blood cell count | 1.239 (1.055–1.455) | 0.009* |
Neutrophil count | 1.257 (1.073–1.472) | 0.005* |
Lymphocyte count | 0.234 (0.051–1.075) | 0.062 |
Platelet count | 0.987 (0.977–0.997) | 0.009* |
Prothrombin time | 1.084 (0.737–1.595) | 0.683 |
Activated partial thromboplastin time | 0.998 (0.979–1.017) | 0.829 |
Creatine kinase | 1.001 (0.999–1.002) | 0.277 |
Creatine kinase-MB | 1.043 (1.008–1.079) | 0.015* |
Lactate dehydrogenase | 1.006 (1.002–1.010) | 0.004* |
Alanine aminotransferase | 1.020 (1.002–1.038) | 0.031* |
Aspartate aminotransferase | 1.034 (1.015–1.054) | < 0.001* |
Total bilirubin | 1.070 (0.995–1.149) | 0.066 |
Blood urea nitrogen | 1.001 (0.985–1.016) | 0.943 |
Creatinine | 1.037 (1.015–1.058) | 0.001* |
Tamiflu | 0.389 (0.047–3.209) | 0.380 |
Variable | Univariable | Multivariable | ||
---|---|---|---|---|
OR (95% CI) | P value | OR (95% CI) | P value | |
Age (years) | 1.102 (1.054–1.152) | < 0.001* | 1.111 (1.042–1.184) | 0.001* |
Male | 6.114 (1.662–22.485) | 0.006* | 7.224 (1.298–40.190) | 0.024* |
Hypertension | 5.000 (1.748–14.301) | 0.003* | 1.099 (0.264–4.580) | 0.897 |
Cardiovascular disease | 7.972 (2.290–27.753) | 0.001* | 1.188 (0.182–7.765) | 0.857 |
Creatinine concentration | 1.037 (1.015–1.058) | 0.001* | 1.012 (0.987–1.037) | 0.342 |